Lipid-based nano-formulation platform for eplerenone oral delivery as a potential treatment of chronic central serous chorioretinopathy: in-vitro optimization and ex-vivo assessment

References

• Abd El-Halim SM, Abdelbary GA, Amin MM, et al. (2020). Stabilized oral nanostructured lipid carriers of adefovir dipivoxil as a potential liver targeting: estimation of liver function panel and uptake following intravenous injection of radioiodinated indicator. J Pharm Sci 28:517–32.
   Web of Science ®Google Scholar
• Abdelbary G, Haider M. (2013). In vitro characterization and growth inhibition effect of nanostructured lipid carriers for controlled delivery of methotrexate. Pharm Dev Technol 18:1159–68.
   PubMed Web of Science ®Google Scholar
• Aburahma MH, Shamma RN, Aburahma MH. (2014). Follicular delivery of spironolactone via nanostructured lipid carriers for management of alopecia. Int J Nanomedicine 9:5449–60.
   PubMed Web of Science ®Google Scholar
• Aburahma MH. (2014). Bile salts-containing vesicles: promising pharmaceutical carriers for oral delivery of poorly water-soluble drugs and peptide/protein-based therapeutics or vaccines. Drug Deliv 1–21; 69–85.
   Google Scholar
• Agrawal Y, Petkar KC, Sawant KK. (2010). Development, evaluation and clinical studies of acitretin loaded nanostructured lipid carriers for topical treatment of Psoriasis. Int J Pharm 401:93–102.
   PubMed Web of Science ®Google Scholar
• Alam S, Aslam M, Khan A, et al. (2016). Nanostructured lipid carriers of pioglitazone for transdermal application: from experimental design to bioactivity detail. Drug Deliv 23:601–609.
   PubMed Web of Science ®Google Scholar
• Almeida S, Pedroso P, Filipe A, et al. (2011). Study on the bioequivalence of two formulations of eplerenone in healthy volunteers under fasting conditions: data from a single-center, randomized, single-dose, open-label, 2-way crossover bioequivalence study. Arzneimittel-Forschung/Drug Res 61:153–159.
   PubMed Web of Science ®Google Scholar
• Alvarez-Trabado J, Diebold Y, Sanchez A. (2017). Designing lipid nanoparticles for topical ocular drug delivery. Int J Pharm 532:204–17.
   PubMed Web of Science ®Google Scholar
• Araújo J, Gonzalez-Mira E, Egea MA, et al. (2010). Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications. Int J Pharm 393:167–75.
   PubMed Web of Science ®Google Scholar
• Bayón-Cordero L, Alkorta I, Arana L. (2019). Application of solid lipid nanoparticles to improve the efficiency of anticancer drugs. Nanomaterials 9:474.
   Web of Science ®Google Scholar
• Bodea A, Leucuta SE. (1997). Optimization of hydrophilic matrix tablets using a D-optimal design. Int J Pharm 51:s91–s97.
   Google Scholar
• Bohorquez M, Koch C, Trygstad T, Pandit N. (1999). A study of the temperature-dependent micellization of pluronic F127. J Colloid Interface Sci 477:94–102.
   Google Scholar
• Bousquet E, Beydoun T, Zhao M, et al. (2013). Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina 33:2096–102.
   PubMed Web of Science ®Google Scholar
• Bouzas EA, Karadimas P, Pournaras CJ. (2002). Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol 47:431–48.
   PubMed Web of Science ®Google Scholar
• Breukink MB, Den Hollander AI, Keunen JEE, et al. (2014). The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy. Acta Ophthalmol 92:e488–e490.
   PubMed Web of Science ®Google Scholar
• Bunjes H, Westesen K, Koch MHJ. (1996). Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Int J Pharm 129:159–73.
   Web of Science ®Google Scholar
• Campos Polo R, Rubio Sánchez C, García Guisado DM, et al. (2018). New treatment for an old problem: retinitis pigmentosa with recalcitrant macular edema. Arch la Soc Española Oftalmol 93:38–41.
   PubMedGoogle Scholar
• Chatziralli I, Vlachodimitropoulou A, Daoula C, et al. (2018). Eplerenone in the treatment of central serous chorioretinopathy: a review of the literature. Int J Retin Vitr 4:1–5. https://doi.org/10.1186/s40942-018-0137-8.
   PubMedGoogle Scholar
• Chen Y, Yang X, Zhao L, et al. (2014). Preparation and characterization of a nanostructured lipid carrier for a poorly soluble drug. Colloids Surf A Physicochem Eng Asp 516:63–71.
   Google Scholar
• Chin EK, Almeida DRP, Roybal CN, et al. (2015). Oral mineralocorticoid antagonists for recalcitrant central serous chorioretinopathy. Clin Ophthalmol 9:1449–56.
   PubMed Web of Science ®Google Scholar
• Cook CS, Berry LM, Bible RH, et al. (2003). Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. Drug Metab Dispos 31:1448–55.
   PubMed Web of Science ®Google Scholar
• Dai WG, Dong LC, Li S, Deng Z. (2008). Combination of pluronic/vitamin E TPGS as a potential inhibitor of drug precipitation. Int J Pharm 355:31–7.
   PubMedGoogle Scholar
• Dan N. (2014). Nanostructured lipid carriers: effect of solid phase fraction and distribution on the release of encapsulated materials. Langmuir 30:13809–14.
   PubMed Web of Science ®Google Scholar
• Daruich A, Matet A, Dirani A, et al. (2016). Oral mineralocorticoid-receptor antagonists: real-life experience in clinical subtypes of nonresolving central serous chorioretinopathy with chronic epitheliopathy. Transl Vis Sci Technol 5:2.
   PubMed Web of Science ®Google Scholar
• Deng J, Huang L, Liu F. (2010). Understanding the structure and stability of paclitaxel nanocrystals. Int J Pharm 390:242–9.
   PubMed Web of Science ®Google Scholar
• Elbary AA, Aboelwafa AA, Al Sharabi IM. (2011). Once daily, high-dose mesalazine controlled-release tablet for colonic delivery: optimization of formulation variables using Box-Behnken design. AAPS PharmSciTech 12:1454–64.
   PubMed Web of Science ®Google Scholar
• Fang C-LA, Al-Suwayeh S, Fang J-Y. (2012). Nanostructured Lipid Carriers (NLCs) for drug delivery and targeting. NANOTEC 7:41–55.
   Web of Science ®Google Scholar
• Furuse M, Choi YH, Mabayo RT, Okumura JI. (1992). Feeding behavior in rats fed diets containing medium chain triglyceride. Physiol Behav 52:815–17.
   PubMed Web of Science ®Google Scholar
• Gemenetzi M, De Salvo G, Lotery AJ. (2010). Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye (Lond) 24:1743–56.
   PubMed Web of Science ®Google Scholar
• Ghasemiyeh P, Mohammadi-Samani S. (2018). Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages. Res Pharm Sci 13:288.
   PubMed Web of Science ®Google Scholar
• Ghosh I, Bose S, Vippagunta R, Harmon F. (2011). Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth. Int J Pharm 409:260.
   PubMed Web of Science ®Google Scholar
• Gordillo-Galeano A, Mora-Huertas CE. (2018). Solid lipid nanoparticles and nanostructured lipid carriers: a review emphasizing on particle structure and drug release. Eur J Pharm Biopharm 133:285–308.
   PubMed Web of Science ®Google Scholar
• Haghighi A, Do J, Ameri H. (2018). Eplerenone as a novel treatment for persistent subretinal fluid following retinal detachment surgery. Am J Ophthalmol Case Rep 10:261–3.
   PubMedGoogle Scholar
• Harisa GI, Badran MM. (2015). Simvastatin nanolipid carriers decreased hypercholesterolemia induced cholesterol inclusion and phosphatidylserine exposure on human erythrocytes. J Mol Liq 208:202–10.
   Web of Science ®Google Scholar
• Hasan F, Pereshki A, Hamishehkar H. (2017). Original research article effect of surfactant and oil type on size droplets of original research article effect of surfactant and oil type on size droplets of betacarotene-bearing nanoemulsions the use of nano carriers for hydrophobic. Int J Curr Microbiol Appl Sci 4:146–55.
   Google Scholar
• Hasani F, Pezeshki A, Hamishehkar H. (2015). Effect of surfactant and oil type on size droplets of betacarotene bearing nanoemulsions. Int J Curr Microbiol Appl Sci 4:146.
   Google Scholar
• Heurtault B, Saulnier P, Pech B, et al. (2003). The influence of lipid nanocapsule composition on their size distribution. Eur J Pharm Sci 18(1):55–61.
   PubMed Web of Science ®Google Scholar
• Hou DZ, Xie CS, Huang KJ, Zhu CH. (2003). The production and characteristics of Solid Lipid Nanoparticles (SLNs). Biomaterials 24:1781–5.
   PubMed Web of Science ®Google Scholar
• Hu FQ, Jiang SP, Du YZ, et al. (2005). Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surfaces B Biointerfaces 45:167–73.
   PubMed Web of Science ®Google Scholar
• Hu FQ, Yuan H, Zhang HH, Fang M. (2002). Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int J Pharm 239:121–28.
   PubMed Web of Science ®Google Scholar
• Huang Y, Bin; Tsai YH, Yang WC, et al. (2004). Once-daily propranolol extended-release tablet dosage form: formulation design and in vitro/in vivo investigation. Eur J Pharm Biopharm 58:607–14.
   PubMed Web of Science ®Google Scholar
• Ibrahim MM, Basalious EB, El-Nabarawi MA. (2020). Consolidated Bile-Based Vesicles/Self-Nanoemulsifying System (CBBVs/SNES) as a solution for limitations of oral delivery of vesicular dispersions: in-vitro optimization and elucidation of ex-vivo intestinal transport mechanisms. J Drug Deliv Sci Technol 56:101489.
   Web of Science ®Google Scholar
• Imam SS, Aqil M, Akhtar M, et al. (2015). Formulation by design-based proniosome for accentuated transdermal delivery of risperidone: in vitro characterization and in vivo pharmacokinetic study. Drug Deliv 22:1059–70.
   PubMed Web of Science ®Google Scholar
• Jenning V, Thünemann AF, Gohla SH. (2000). Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm 199:167–77.
   PubMed Web of Science ®Google Scholar
• Joshi M, Patravale V. (2006). Formulation and evaluation of Nanostructured Lipid Carrier (NLC)-based gel of valdecoxib. Drug Dev Ind Pharm 32:911–8.
   PubMed Web of Science ®Google Scholar
• Kendre PN, Chaudhari PD. (2017). Effect of polyvinyl caprolactam–polyvinyl acetate–polyethylene glycol graft copolymer on bioadhesion and release rate property of eplerenone pellets. Drug Dev Ind Pharm 43:751–61.
   PubMed Web of Science ®Google Scholar
• Khames A. (2019). Formulation and characterization of eplerenone nanoemulsion liquisolids, an oral delivery system with higher release rate and improved bioavailability. Pharmaceutics 11:40.
   PubMed Web of Science ®Google Scholar
• Khan S, Baboota S, Ali J, et al. (2015). Nanostructured lipid carriers: an emerging platform for improving oral bioavailability of lipophilic drugs. Int J Pharm Investig 5:182.
   PubMed Web of Science ®Google Scholar
• Kovačević AB, Müller RH, Savić SD, et al. (2014). Solid Lipid Nanoparticles (SLN) stabilized with polyhydroxy surfactants: preparation, characterization and physical stability investigation. Colloids Surf A Physicochem Eng Asp 444:15–25.
   Web of Science ®Google Scholar
• Kumbhar DD, Pokharkar VB. (2013). Engineering of a nanostructured lipid carrier for the poorly water-soluble drug, bicalutamide: physicochemical investigations. Colloids Surf A Physicochem Eng Asp 416:32–4.
   Web of Science ®Google Scholar
• Nakashima H, Suzuki H, Ohtsu H, et al. (2006). Angiotensin II regulates vascular and endothelial dysfunction: recent topics of angiotensin II type-1 receptor signaling in the vasculature. Curr Vasc Pharmacol 4:67–78.
   PubMedGoogle Scholar
• Niu M, Tan Y, Guan P, et al. (2014). Enhanced oral absorption of insulin-loaded liposomes containing bile salts: a mechanistic study. Int J Pharm 460:119–30.
   PubMed Web of Science ®Google Scholar
• Özdemir S, Çelik B, Sümer E, et al. (2018a). Eplerenone nanoemulsions for treatment of hypertension. Part II: physical stability assessment and in vivo study. J Drug Deliv Sci Technol 45:287–95.
   Web of Science ®Google Scholar
• Özdemir S, Çelik B, Türköz Acar E, et al. (2018b). Eplerenone nanoemulsions for treatment of hypertension. Part I: experimental design for optimization of formulations and physical characterization. J Drug Deliv Sci Technol 45:287–95.
   Web of Science ®Google Scholar
• Pichi F, Carrai P, Ciardella A, et al. (2015). Comparison of two mineralocorticoid receptor antagonists in the treatment of central serous chorioretinopathy. Investig Ophthalmol Vis Sci 56:1284.
   Web of Science ®Google Scholar
• Pandya VM, Patel JK, Patel DJ. (2011). Formulation and optimization of nanosuspensions for enhancing simvastatin dissolution using central composite design. Dissolution Technol 18:40–5.
   Web of Science ®Google Scholar
• Patil GB, Patil ND, Deshmukh PK, et al. (2016). Nanostructured lipid carriers as a potential vehicle for carvedilol delivery: application of factorial design approach. Artif Cells Nanomed Biotechnol 44:12–19.
   PubMed Web of Science ®Google Scholar
• Patil-Gadhe A, Pokharkar V. (2014). Montelukast-loaded nanostructured lipid carriers: Part I: oral bioavailability improvement. Eur J Pharm Biopharm 88:169–77.
   PubMed Web of Science ®Google Scholar
• Pichi F, Carrai P, Ciardella A, et al. (2017). Comparison of two mineral corticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. Int Ophthalmol 35:167–71.
   Google Scholar
• Poonia N, Kharb R, Lather V, Pandita D. (2016). Nanostructured lipid carriers: versatile oral delivery vehicle. Future Sci Oa 2:FSO135.
   PubMed Web of Science ®Google Scholar
• Radtke M, Souto EB, Müller RH. (2005). Nanostructured lipid carriers: a novel generation of solid lipid drug carriers. Pharm Technol Eur 17:45–50.
   Google Scholar
• Rane V, Patil K, Sangshetti J, et al. (2009). Stability-indicating RP-HPLC method for analysis of eplerenone in the bulk drug and in a pharmaceutical dosage form. Acta Chromatogr 21:619–9.
   Web of Science ®Google Scholar
• Salehi M, Wenick AS, Law HA, et al. (2015). Interventions for central serous chorioretinopathy: a network meta-analysis. Cochrane Database Syst Rev 12:CD011841.
   Google Scholar
• Salz DA, Pitcher JD, Hsu J, et al. (2015). Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series. Ophthalmic Surg. Lasers Imaging Retin 46:439–44.
   PubMed Web of Science ®Google Scholar
• Sanad RA, Abdelmalak NS, Tahany S, Badawi AA. (2010). Formulation of a novel oxybenzone-loaded nanostructured lipid carriers (NLCs). AAPS PharmSciTech 11:1684–94.
   PubMed Web of Science ®Google Scholar
• Saupe A, Gordon KC, Rades T. (2006). Structural investigations on nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers by Cryo-Field Emission Scanning Electron Microscopy and Raman Spectroscopy. Int J Pharm 314:56–62.
   PubMed Web of Science ®Google Scholar
• Savaskan E, Löffler KU, Meier F, et al. (2004). Immunohistochemical localization of angiotensin-converting enzyme, angiotensin II and AT1 receptor in human ocular tissues. Ophthalmic Res 36:312–20.
   PubMed Web of Science ®Google Scholar
• Sayed S, Habib BA, Elsayed GM. (2018). Tri-block co-polymer nanocarriers for enhancement of oral delivery of felodipine: preparation, in vitro characterization and ex vivo permeation. J Liposome Res 28:182–92.
   PubMed Web of Science ®Google Scholar
• Schwarz C, Mehnert W. (1999). Solid Lipid Nanoparticles (SLN) for controlled drug delivery. II. Drug incorporation and physicochemical characterization. J Microencapsul 1:205–13.
   Google Scholar
• Shah RM, Malherbe F, Eldridge D, et al. (2014). Physicochemical characterization of Solid Lipid Nanoparticles (SLNs) prepared by a novel microemulsion technique. J Colloid Interface Sci 428:286–94.
   PubMed Web of Science ®Google Scholar
• Shahgaldian P, Da Silva E, Coleman AW, et al. (2003). Para-Acyl-Calix-Arene based Solid Lipid Nanoparticles (SLNs): a detailed study of preparation and stability parameters. Int J Pharm 253:23–38.
   PubMed Web of Science ®Google Scholar
• Shete H, Patravale V. (2013). Long chain lipid based tamoxifen NLC. Part I: preformulation studies, formulation development and physicochemical characterization. Int J Pharm 454:573–83.
   PubMed Web of Science ®Google Scholar
• Souto EB, Müller RH. (2010). Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes. Handb Exp Pharmacol 197:115–41.
   PubMedGoogle Scholar
• Üner M, Karaman EF, Aydoǧmuş Z. (2014). Solid lipid nanoparticles and nanostructured lipid carriers of loratadine for topical application: physicochemical stability and drug penetration through rat skin. Trop J Pharm Res 13:653–60.
   Web of Science ®Google Scholar
• Uprit S, Kumar Sahu R, Roy A, Pare A. (2013). Preparation and characterization of minoxidil loaded nanostructured lipid carrier gel for effective treatment of alopecia. Saudi Pharm J 21:379–85.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhu R, Sun X, et al. (2014). Intracellular uptake of etoposide-loaded solid lipid nanoparticles induces an enhancing inhibitory effect on gastric cancer through mitochondria-mediated apoptosis pathway. Int J Nanomedicine 9:3987–98.
   PubMed Web of Science ®Google Scholar
• Weerapol Y, Limmatvapirat S, Nunthanid J, Sriamornsak P. (2014). Self-nanoemulsifying drug delivery system of nifedipine: impact of hydrophilic-lipophilic balance and molecular structure of mixed surfactants. AAPS PharmSciTech 15:456–64.
   PubMed Web of Science ®Google Scholar
• Westesen K, Siekmann B, Koch MHJ. (1993). Investigations on the physical state of lipid nanoparticles by synchrotron radiation X-ray diffraction. Int J Pharm 93:189–99.
   Web of Science ®Google Scholar
• Yang D, Eliott D. (2017). Systemic mineralocorticoid antagonists in the treatment of central serous chorioretinopathy. Semin Ophthalmol 32:36–42.
   PubMed Web of Science ®Google Scholar
• Yu Y, Feng R, Yu S, et al. (2018). Nanostructured lipid carrier-based PH and temperature dual-responsive hydrogel composed of carboxymethyl chitosan and poloxamer for drug delivery. Int J Biol Macromol 114:462–9.
   PubMed Web of Science ®Google Scholar
• Zeng L, Xin X, Zhang Y. (2017). Development and characterization of promising cremophor EL-stabilized o/w nanoemulsions containing short-chain alcohols as a cosurfactant. RSC Adv 7:19815–27.
   Web of Science ®Google Scholar
• Zhao M, Célérier I, Bousquet E, et al. (2012). Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest 122:2672–9.
   PubMed Web of Science ®Google Scholar
• Zhao M, Valamanesh F, Celerier I, et al. (2010). The neuroretina is a novel mineralocorticoid target: aldosterone up‐regulates ion and water channels in Müller Glial cells. FASEB J 24:3405–15.
   PubMed Web of Science ®Google Scholar